|
1.
|
Heldin CH, Eriksson U and Ostman A: New
members of the platelet-derived growth factor family of mitogens.
Arch Biochem Biophys. 398:284–290. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Fredriksson L, Li H and Eriksson U: The
PDGF family: four gene products form five dimeric isoforms.
Cytokine Growth Factor Rev. 15:197–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Betsholtz C, Johnsson A, Heldin CH,
Westermark B, Lind P, Urdea MS, Eddy R, Shows TB, Philpott K and
Mellor AL: cDNA sequence and chromosomal localization of human
platelet-derived growth factor A-chain and its expression in tumour
cell lines. Nature. 320:695–699. 1986. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Heldin CH and Westermark B: Mechanism of
action and in vivo role of platelet-derived growth factor. Physiol
Rev. 79:1283–1316. 1999.PubMed/NCBI
|
|
5.
|
Li X, Pontén A, Aase K, Karlsson L,
Abramsson A, Uutela M, Bäckström G, Hellström M, Boström H, Li H,
Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A and Eriksson
U: PDGF-C is a new protease-activated ligand for the PDGF
alpha-receptor. Nat Cell Biol. 2:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
LaRochelle WJ, Jeffers M, McDonald WF,
Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M,
Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets
J, Shimkets RA, Rothberg JM and Lichenstein HS: PDGF-D, a new
protease-activated growth factor. Nat Cell Biol. 3:517–521. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Reigstad LJ, Varhaug JE and Lillehaug JR:
Structural and functional specificities of PDGF-C and PDGF-D, the
novel members of the platelet-derived growth factors family. FEBS
J. 272:5723–5741. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Betsholtz C: Biology of platelet-derived
growth factors in development. Birth Defects Res C Embryo Today.
69:272–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Andrae J, Gallini R and Betsholtz C: Role
of platelet-derived growth factors in physiology and medicine.
Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Betsholtz C, Lindblom P, Bjarnegard M,
Enge M, Gerhardt H and Lindahl P: Role of platelet-derived growth
factor in mesangium development and vasculopathies: lessons from
platelet-derived growth factor and platelet-derived growth factor
receptor mutations in mice. Curr Opin Nephrol Hypertens. 13:45–52.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Floege J, Eitner F and Alpers CE: A new
look at platelet-derived growth factor in renal disease. J Am Soc
Nephrol. 19:12–23. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bonner JC: Regulation of PDGF and its
receptors in fibrotic diseases. Cytokine Growth Factor Rev.
15:255–273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Raines EW: PDGF and cardiovascular
disease. Cytokine Growth Factor Rev. 15:237–254. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Floege J, Eitner F, Van Roeyen C and
Ostendorf T: PDGF-D and renal disease: yet another one of those
growth factors? J Am Soc Nephrol. 14:2690–2691. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ostendorf T, van Roeyen CR, Peterson JD,
Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J,
Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ and
Floege J: A fully human monoclonal antibody (CR002) identifies
PDGF-D as a novel mediator of mesangioproliferative
glomerulonephritis. J Am Soc Nephrol. 14:2237–2247. 2003.
View Article : Google Scholar
|
|
16.
|
van Roeyen CR, Ostendorf T, Denecke B,
Bokemeyer D, Behrmann I, Strutz F, Lichenstein HS, LaRochelle WJ,
Pena CE, Chaudhuri A and Floege J: Biological responses to PDGF-BB
versus PDGF-DD in human mesangial cells. Kidney Int. 69:1393–1402.
2006.PubMed/NCBI
|
|
17.
|
Rios A, Vargas-Robles H, Gámez-Méndez AM
and Escalante B: Cyclooxygenase-2 and kidney failure.
Prostaglandins Other Lipid Mediat. 98:86–90. 2012. View Article : Google Scholar
|
|
18.
|
Schneider A and Stahl RA: Cyclooxygenase-2
(COX-2) and the kidney: current status and potential perspectives.
Nephrol Dial Transplant. 13:10–12. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Krämer BK, Kammerl MC and Kömhoff M: Renal
cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and
clinical implications. Kidney Blood Press Res. 27:43–62.
2004.PubMed/NCBI
|
|
20.
|
Giovanni G and Giovanni P: Do
non-steroidal anti-inflammatory drugs and COX-2 selective
inhibitors have different renal effects? J Nephrol. 15:480–488.
2002.PubMed/NCBI
|
|
21.
|
Smith WL, DeWitt DL and Garavito RM:
Cyclooxygenases: structural, cellular, and molecular biology. Annu
Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Smith WL and DeWitt DL: Prostaglandin
endoperoxide H synthases-1 and -2. Adv Immunol. 62:167–215. 1996.
View Article : Google Scholar
|
|
23.
|
Hla T and Neilson K: Human
cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 89:7384–7388. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Mitchell JA, Belvisi MG, Akarasereenont P,
Robbins RA, Kwon OJ, Croxtall J, Barnes PJ and Vane JR: Induction
of cyclooxygenase-2 by cytokines in human pulmonary epithelial
cells: regulation by dexamethasone. Br J Pharmacol. 113:1008–1014.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wadleigh DJ, Reddy ST, Kopp E, Ghosh S and
Herschman HR: Transcriptional activation of the cyclooxygenase-2
gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem.
275:6259–6266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Jang BC: Induction of COX-2 in human
airway cells by manganese: role of PI3K/PKB, p38 MAPK, PKCs, Src,
and glutathione depletion. Toxicol In Vitro. 23:120–126. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Xu K, Chang CM, Gao H and Shu HK:
Epidermal growth factor-dependent cyclooxygenase-2 induction in
gliomas requires protein kinase C-delta. Oncogene. 28:1410–1420.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Wang D and Dubois RN: The role of COX-2 in
intestinal inflammation and colorectal cancer. Oncogene.
29:781–788. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hirose S, Yamamoto T, Feng L, Yaoita E,
Kawasaki K, Goto S, Fujinaka H, Wilson CB, Arakawa M and Kihara I:
Expression and localization of cyclooxygenase isoforms and
cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. J Am
Soc Nephrol. 9:408–416. 1998.PubMed/NCBI
|
|
30.
|
Khan KN, Stanfield KM, Harris RK and Baron
DA: Expression of cyclooxygenase-2 in the macula densa of human
kidney in hypertension, congestive heart failure, and diabetic
nephropathy. Ren Fail. 23:321–330. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Wang JL, Cheng HF, Shappell S and Harris
RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria
and retards progressive renal injury in rats. Kidney Int.
57:2334–2342. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Cheng HF, Wang CJ, Moeckel GW, Zhang MZ,
McKanna JA and Harris RC: Cyclooxygenase-2 inhibitor blocks
expression of mediators of renal injury in a model of diabetes and
hypertension. Kidney Int. 62:929–939. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Goppelt-Struebe M, Rehm M and Schaefers
HJ: Induction of cyclooxygenase-2 by platelet-derived growth factor
(PDGF) and its inhibition by dexamethasone are independent of
NF-kappaB/IkappaB transcription factors. Naunyn Schmiedebergs Arch
Pharmacol. 361:636–345. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Xu K, Kitchen CM, Shu HK and Murphy TJ:
Platelet-derived growth factor-induced stabilization of
cyclooxygenase 2 mRNA in rat smooth muscle cells requires the c-Src
family of protein-tyrosine kinases. J Biol Chem. 282:32699–32709.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Nakao S, Ogata Y, Yamamoto Y, Furuyama S
and Sugiya H: Platelet-derived growth factor-induced arachidonic
acid release for enhancement of prostaglandin E(2) synthesis in
human gingival fibroblasts pretreated with interleukin-1beta. J
Cell Biochem. 92:579–590. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Dean JL, Brook M, Clark AR and Saklatvala
J: p38 mitogen-activated protein kinase regulates cyclooxygenase-2
mRNA stability and transcription in lipopolysaccharide-treated
human monocytes. J Biol Chem. 274:264–269. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Guan Z, Buckman SY, Miller BW, Springer LD
and Morrison AR: Interleukin-1beta-induced cyclooxygenase-2
expression requires activation of both c-Jun NH2-terminal kinase
and p38 MAPK signal pathways in rat renal mesangial cells. J Biol
Chem. 273:28670–28676. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Ammoun S, Flaiz C, Ristic N, Schuldt J and
Hanemann CO: Dissecting and targeting the growth factor-dependent
and growth factor-independent extracellular signal-regulated kinase
pathway in human schwannoma. Cancer Res. 68:5236–5245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Okada A, Yaguchi T, Kanno T, Gotoh A,
Nakano T and Nishizaki T: PDGF-D/PDGF-ββ receptor-regulated
chemotaxis of malignant mesothelioma cells. Cell Physiol Biochem.
29:241–250. 2012.
|
|
40.
|
Borkham-Kamphorst E, van Roeyen CR,
Ostendorf T, Floege J, Gressner AM and Weiskirchen R:
Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol.
46:1064–1074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Menè P, Abboud HE and Dunn MJ: Regulation
of human mesangial cell growth in culture by thromboxane A2 and
prostacyclin. Kidney Int. 38:232–239. 1990.PubMed/NCBI
|
|
42.
|
Stahl RA, Thaiss F, Haberstroh U, Kahf S,
Shaw A and Schoeppe W: Cyclooxygenase inhibition enhances rat
interleukin 1 beta-induced growth of rat mesangial cells in
culture. Am J Physiol. 259:419–424. 1990.PubMed/NCBI
|
|
43.
|
Zahner G, Wolf G, Ayoub M, Reinking R,
Panzer U, Shankland SJ and Stahl RA: Cyclooxygenase-2
overexpression inhibits platelet-derived growth factor-induced
mesangial cell proliferation through induction of the tumor
suppressor gene p53 and the cyclin-dependent kinase inhibitors
p21waf-1/cip-1 and p27kip-1. J Biol Chem. 277:9763–9771. 2002.
View Article : Google Scholar
|
|
44.
|
Trifan OC, Smith RM, Thompson BD and Hla
T: Overexpression of cyclooxygenase-2 induces cell cycle arrest.
Evidence for a prostaglandin-independent mechanism. J Biol Chem.
274:34141–34147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Shibata T, Tamura M, Kabashima N, Serino
R, Tokunaga M, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y,
Takeuchi M, Abe H, Okazaki M and Otsuji Y: Fluvastatin attenuates
IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic
acid depletion in human mesangial cells. Life Sci. 84:725–731.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Mitchell D, Rodgers K, Hanly J, McMahon B,
Brady HR, Martin F and Godson C: Lipoxins inhibit Akt/PKB
activation and cell cycle progression in human mesangial cells. Am
J Pathol. 164:937–946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Bassa BV, Noh JW, Ganji SH, Shin MK, Roh
DD and Kamanna VS: Lysophosphatidylcholine stimulates EGF receptor
activation and mesangial cell proliferation: regulatory role of Src
and PKC. Biochim Biophys Acta. 1771:1364–1371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Tokuyama H, Kim S, Zhang Y, Langham RG,
Cox AJ, Gow RM, Kelly DJ and Gilbert RE: Protein kinase C β
inhibition ameliorates experimental mesangial proliferative
glomerulonephritis. Nephrology (Carlton). 16:649–655. 2011.
|
